Denali Therapeutics (DNLI) logo

Denali Therapeutics (DNLI) stock

Brain disease therapeutics , market cap $2.9B

After-hours Fri
$18.19
-1.41%

Close $18.45 +1.37%

Quality Score
-2
Poor
In its industry
#139of 273
Checks firing
1of 14
Choppy
From 52-week high
-32.4%
under its best in a year

DNLI's Quality Score was unchanged on Fri, Nov 20, at -2.

Follow DNLI's trial news. Pro members can get an alert when Denali Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when DNLI files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ1 2027“…plans to present additional data from the Phase 1/2 study at a medical congress in the first quarter of 2027…”Trial data · SEC filing · Nov 3
Cash$1.0B, about 9 quarters (2.5 years) at the last year's spendingOn Sep 30

Why is DNLI up?

Up 8% on Nov 4, an up day for the market: the S&P 500 rose 2%, 72% of stocks rose, and biotech stocks a median 2.1%.

“AVLAYAH's U.S. launch gained significant momentum, driven by strong demand from families across the eligible patient population”

Denali Therapeutics' Nov 3 release said

Sources: Price history, Nov 4, 2026; Company release, Nov 3, 2026

1 more reason, free with an account →See every reason on DNLI →2 more reasons why DNLI rose on Nov 4, from its filings, with the other side, how the business stands, the company's words, the timeline, and its peers, for Pro members.

Why DNLI still lags the market over five years

Down 59% over the five years to Nov 20 while the S&P 500 rose 58%; up 8% on Nov 4.

3 reasons, from its filings, with the timeline and its peers, for Pro members.

Key facts on DNLI

Key facts on DNLI
Holding it backBelow a falling 200-day average down over two years
Latest filing8-K, Nov 3 Reported its quarterly results
Cash$1.0B, about 9 quarters (2.5 years) at the last year's spendingOn Sep 30

DNLI catalysts

Coming up

After its last 4 reports it closed +1.6% on average, higher 2 of 4 times.

7 more coming up and 12 past catalysts since 2018, with sizes and sources, for Pro members.

What's next for DNLI, and how long its cash lasts

Next step the company has named

Q1 2027“Denali plans to present additional data from the Phase 1/2 study at a medical congress in the first quarter of 2027.”Trial data · SEC filing · Nov 3

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007Phase 2/3 · By invitation · 99 people · main data estimated Jun 2027 · NCT06075537

8 more trials, 1 with data due this year, 5 more milestones and 36 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 9 quarters

$1.0B in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Feb 27, 2025)
  • At-the-market share sales program (S-3ASR, filed Feb 27, 2025)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Chief Medical Officer Peter Scott Chin sold 1,654 shares on Sep 4. 5 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Ryan Watts’s 17 filings and quotes.

Get an alert when DNLI files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why DNLI scores -2

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

  • +1Chart checks 1 of 14 firing right now, one point each
  • −2Long-term trend below a falling 200-⁠day average, down over two years
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Profit, Growth, Dilution, Volatility, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on DNLI and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:34 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when DNLI's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How DNLI ranks in Biotech

DNLI is #139 of 273 by Quality Score.

How DNLI ranks in Biotech
RankStockQuality Score
139Denali Therapeutics (DNLI) logoDNLIDenali Therapeutics-2

Net income over four quarters: DNLI -$314M, HALO $485M, BEAM -$108M, IMVT -$509M.

More in Biotech

When does DNLI report earnings, and what happens after?

Expected to report Thu Feb 25, after the close (in 96 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What DNLI reported on Nov 3, 2026

The quarter

A profit of $0.37 a share, from a loss of $0.74.

“AVLAYAH's U.S. launch gained significant momentum, driven by strong demand from families across the eligible patient population, physicians committed to treating their patients and rapidly expanding payer coverage.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

DNLI's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
MeasureFigure
Q4 2026
AVLAYAH net product revenue$30M to $32M

Figures as filed (SEC filing, Nov 3)

In the company's words

  • “The $2.0 million increase primarily reflected higher commercial and medical affairs costs to support the AVLAYAH launch, along with higher site and personnel costs.”

From its results filing (SEC filing · Nov 3)

The numbers

Market value
$2.9B
today
Free cash flow
-$450M
last 12 months

Its share count grew 8.9% a year over 5 years.

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on DNLI: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-0.5%+0.4%+7.8%
May 7Aug 6Nov 3
ReportedGapReaction5
days
Nov 3, 2026After close+9.2%+7.8%+2.1%
Aug 6, 2026After close+2.8%+0.4%+0.4%
May 7, 2026After close-1.4%-0.5%-1.6%

DNLI closed higher after 2 of its last 4 reports.

All 4 reports, and DNLI's Quality Score going into each

DNLI sales and profit by year

Sales and profit by year

Sales grew in three of the last seven years, to $0 in 2025. It made a profit in one of the eight years.

DNLI has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on DNLI, and all 14 on every stock.Get in free →See the top 3 →Start Pro

DNLI RSI on Nov 20: 43.8, below its 50-day and 200-day averages

Not scored

RSI 43.8, MACD below signal, below both averages. Not scored.

The deep dive on DNLI

7 more findings on DNLI, each with its source, for Pro members.

DNLI share count over time

9% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of DNLI outstanding, as filed
Shares
outstanding
As
of
160.3MOct 28, 2026
159.8MJul 31, 2026
158.7MMay 1, 2026
158.6MFeb 20, 2026
Offerings, shelves, and splits of DNLI, from its filings
From its
filings
Filed
Raised $160M in a sale of shares, about 5% of its market valueDec 10, 2025
Registered shares for a later sale (S-3ASR)Feb 27, 2025
Registered shares for a later sale (S-3ASR)Mar 22, 2024

DNLI insider trades

2 insiders sold $108K across 2 filings in the last 6 months. No open-⁠market buys on record. The newest:

SellPeter Scott Chin$37KChief Medical Officerat $22.29 on Sep 4, filed Sep 9

DNLI's officers and directors

Officers and directors with a Form 4 in the last 12 months.

4 more officers and directors file at DNLI.

See insider trades by person

Which ETFs hold DNLI?

In ETFs: DNLI is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.

507 employeesSouth San Francisco, CAdenalitherapeutics.com

What Denali Therapeutics says it competes with

“The biotechnology and pharmaceutical industries, including in the neurodegenerative disease field, are characterized by rapidly advancing technologies, strong competition and an emphasis on intellectual property.”

From its annual report, SEC filing · Feb 26, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on DNLI and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn DNLI's score around: 6 things
  • 5 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawaySep 9Peter Scott Chin sold DNLI$37K at $22.29, filed Sep 9

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: DNLI's Quality Score is -2 (Poor), #139 of 273 in Biotech. Insiders sold $108K in the last 6 months (Form 4).

What does DNLI's Quality Score say?

DNLI scores -2 today, which Breakaway calls Poor. It is #139 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Up 8% on Nov 4, an up day for the market: the S&P 500 rose 2%, 72% of stocks rose, and biotech stocks a median 2.1%. Cash lasts about 9 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is DNLI's Quality Score?

DNLI scores -2 today, which Breakaway calls Poor (below zero). That is #139 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DNLI's -2.

Are insiders buying DNLI?

2 insiders sold $108K across 2 filings in the last 6 months. No open-⁠market buys on record. The newest is Peter Scott Chin, Chief Medical Officer, who sold $37K on Sep 4. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Denali Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.